14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
FDMT vs STOK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, 4D Molecular Therapeutics, Inc. (FDMT) is the stronger overall head-to-head candidate over Stoke Therapeutics, Inc. (STOK) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FDMT carries a Unified Composite Score of 42.1/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin), whereas STOK carries 55.8/100 (HOLD) at $26.54 (N/M Forward P/E, -913.2% operating margin).
Composite vs. Pillar Nuance: While STOK currently prints a higher short-term Unified Composite Score (55.8/100 HOLD vs. FDMT 42.1/100 HOLD), FDMT captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-222.7% vs. -913.2% operating margin) and revenue trajectory (+4505.6% vs. +5.9% YoY).
Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile STOK trades in a Neutral technical trend (SURGE options phase, RSI 52.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $1.7B market capitalization and -913.2% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ FDMT vs STOK Key Questions & Quantitative Answers
As of Nov 16, 2026, 4D Molecular Therapeutics, Inc. (FDMT) is the stronger overall head-to-head candidate over Stoke Therapeutics, Inc. (STOK) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FDMT carries a Unified Composite Score of 42.1/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin), whereas STOK carries 55.8/100 (HOLD) at $26.54 (N/M Forward P/E, -913.2% operating margin). Composite vs. Pillar Nuance: While STOK currently prints a higher short-term Unified Composite Score (55.8/100 HOLD vs. FDMT 42.1/100 HOLD), FDMT captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-222.7% vs. -913.2% operating margin) and revenue trajectory (+4505.6% vs. +5.9% YoY). Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile STOK trades in a Neutral technical trend (SURGE options phase, RSI 52.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
FDMT leads the Growth & Scale pillar: FDMT posts +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin), compared with STOK at +5.9% YoY revenue growth and +0.0% YoY earnings growth on $28M TTM revenue (100.0% gross margin, -913.2% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), FDMT cumulative revenue shifted +800.0% while STOK shifted +1700.0%. In operating R&D and SG&A reinvestment, FDMT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for STOK.
FDMT screens cheaper on headline valuation multiples. FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin), whereas STOK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 57.0x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FDMT (-56.7% ROE) versus STOK (-73.6% ROE) capital efficiency.
In options market volatility and institutional positioning, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk). By comparison, STOK carries 63.5% implied volatility (8th %ile, Compressed (<25th %ile)), a 3.80x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (0.99β · 47% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.